Make no mistake: Cancer is one of the biggest health challenges worldwide.

Quick view on one of the cancer foundation:

Since they starting the research in 2011/12, the percentage of all deaths from cancer has risen from 9.6% in 2011 to 14.9% 10 years later; in the last 5 years this has risen again to where we now have 16.2% of all deaths recorded as cancer deaths.

Taking into consideration that in the period 2019-2024 the average European and the United Kingdom population was 760.3 million, an average 4,880,664 new cases were reported yearly during the same period. This is an ASR of 280, and a cumulative risk of 29.1%.

Breast, Colorectum, and Lung cancers were the most common cancers across both sexes. The male population in this period, some 370.2 million, recorded an average of 2,482,117 new cancer cases per year; an ASR of 321.4 per 100,000 and a cumulative risk of 33.1%.

The top 3 most common cancers among males were Prostate, Lung, and Colorectum cancer.

The female population in this period, some 390.1 million, recorded an average 2,398,547 new cancer cases per year; an ASR of 258.6 and a cumulative risk of 26.5%.

The top 3 most common cancers in females were Breast, Colorectum, and Lung cancer.

A significant point with cancer in the female population was the drop in lung cancer to 3rd place, with colorectum cancer overtaking to 2nd place.

Their mortality database is a collection of death registration data which includes cause of death information from member states; we use only the data which has been properly coded to the International Classification of Diseases (ICD).

What has also changed in recent years is the age of death rate. This had declined over time in several countries due to life improvements, early diagnoses, medical advances, and a general reduction in risk factors like smoking. However, there is a worrying emerging trend with rates of cancer in the population group aged up to 16.

This is rising well over expectations, especially in the United Kingdom, Spain and France.

Do we have answer: Not really, because there is no solution to end all these “cold wars” between the pharmaceutical giants and others researchers. They will never ever join the forces therefore in research and development so far the cancer is concern there is (and will be) impossible to join the forces, because they will never ever be able to draw the line between whose invention or development was more crucial for the final products.